Latest news with #AdaptHealthCorp
Yahoo
16-07-2025
- Business
- Yahoo
Truist Financial Remains Bullish on AdaptHealth (AHCO)
AdaptHealth Corp. (NASDAQ:AHCO) is one of the best undervalued medical device stocks to buy now. In a report released on July 1, David S Macdonald from Truist Financial maintained a Buy rating on AdaptHealth Corp. (NASDAQ:AHCO) without a price target. A healthcare professional wearing a face mask and surgical gloves operating a medical device in a clinical setting. AdaptHealth Corp. (NASDAQ:AHCO) reported $95.5 million in cash flow from operations in fiscal Q1 2025, an increase from $49.0 million. Free cash flow for the quarter reached negative $0.1 million, compared to negative $38.9 million previously. Net revenue for the quarter, however, underwent a 1.8% decline to $777.9 million. AdaptHealth Corp. (NASDAQ:AHCO) provides home healthcare equipment, supplies, and related services. The company's focus is on sleep therapy equipment for obstructive sleep apnea, oxygen, and related chronic therapy services, HME medical devices and supplies for wound care, diabetes, urological, and more. While we acknowledge the potential of AHCO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Business Wire
15-07-2025
- Business
- Business Wire
AdaptHealth Corp. Announces Second Quarter 2025 Earnings Release Date and Conference Call
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)-- AdaptHealth Corp. (NASDAQ: AHCO) ('AdaptHealth' or the 'Company'), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, will release its second quarter 2025 financial results before the opening of the financial markets on Tuesday, August 5, 2025. Management will host a teleconference at 8:30 a.m. ET to discuss the results and business activities with analysts and investors. Interested parties may participate in the call by dialing: (800) 343-4136 (Domestic) or (203) 518-9843 (International) When prompted, reference Conference ID: AHCO2Q25 Webcast registration: Click Here Following the live call, a replay will be available for six months on the Company's website, under "Investor Relations." About AdaptHealth Corp. AdaptHealth is a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services. The Company operates under four reportable segments that align with its product categories: (i) Sleep Health, (ii) Respiratory Health, (iii) Diabetes Health, and (iv) Wellness at Home. The Sleep Health segment provides sleep therapy equipment, supplies and related services (including CPAP and BiLevel services) to individuals for the treatment of obstructive sleep apnea. The Respiratory Health segment provides oxygen and home mechanical ventilation equipment and supplies and related chronic therapy services to individuals for the treatment of respiratory diseases, such as chronic obstructive pulmonary disease and chronic respiratory failure. The Diabetes Health segment provides medical devices, including continuous glucose monitors and insulin pumps, and related services to patients for the treatment of diabetes. The Wellness at Home segment provides home medical equipment and services to patients in their homes including those who have been discharged from acute care and other facilities. The segment tailors a service model to patients who are adjusting to new lifestyles or navigating complex disease states by providing essential medical supplies and durable medical equipment. The Company is proud to partner with an extensive and highly diversified network of referral sources, including acute care hospitals, sleep labs, pulmonologists, skilled nursing facilities, and clinics. AdaptHealth services beneficiaries of Medicare, Medicaid, and commercial insurance payors, reaching approximately 4.2 million patients annually in all 50 states through its network of approximately 660 locations in 47 states.
Business Wire
30-06-2025
- Business
- Business Wire
AdaptHealth Corp. Closes Transaction to Dispose of Certain Home Infusion Assets and Reduces Debt
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AdaptHealth Corp. (NASDAQ: AHCO) ('AdaptHealth' or the 'Company'), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, today announced that it has closed on the previously disclosed disposition of certain infusion assets in its Wellness at Home segment to a third party. The transaction was completed earlier this month. 'The disposition of certain infusion assets marks yet another significant step in our effort to sharpen our strategic focus by exiting ancillary product lines,' said AdaptHealth CEO, Suzanne Foster. 'Additionally, the sale advances our commitment to debt reduction to unlock value for our shareholders.' The Company used the proceeds of the disposition, and other funds, to make a prepayment of $65.0 million on its outstanding term loan. This prepayment was in addition to a previously announced $70.0 million prepayment on the term loan in May, funded primarily with proceeds from the sale of certain incontinence assets. The products included in the disposition of certain infusion assets represented approximately $52 million of annual revenue and approximately $5 million of annual Adjusted EBITDA. Additionally, the Company projects $30 million of cash taxes due on the gains from this disposition. To reflect these impacts, the Company is revising its full-year revenue guidance to a range of $3,150 million to $3,290 million, its full-year 2025 Adjusted EBITDA to a range of $662 million to $702 million, and its full-year 2025 Free Cash Flow to a range of $170 million to $190 million. About AdaptHealth Corp. AdaptHealth is a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment (HME), medical supplies, and related services. The Company provides a full suite of medical products and solutions designed to help patients manage chronic conditions in the home, adapt to challenges in their activities of daily living, and thrive. Product and service offerings include (i) sleep therapy equipment, supplies, and related services (including CPAP and bi PAP services) to individuals suffering from obstructive sleep apnea, (ii) medical devices and supplies to patients for the treatment of diabetes (including continuous glucose monitors and insulin pumps), (iii) HME to patients discharged from acute care and other facilities, (iv) oxygen and related chronic therapy services in the home, and (v) other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy and nutritional supply needs. The Company is proud to partner with an extensive and highly diversified network of referral sources, including acute care hospitals, sleep labs, pulmonologists, skilled nursing facilities, and clinics. AdaptHealth services beneficiaries of Medicare, Medicaid, and commercial insurance payors, reaching approximately 4.2 million patients annually in all 50 states through its network of approximately 670 locations in 47 states. Forward-Looking Statements This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as 'believe,' 'may,' 'will,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'expect,' 'should,' 'would,' 'plan,' 'predict,' 'potential,' 'seem,' 'seek,' 'future,' 'outlook,' and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding projections, estimates and forecasts of revenue and other financial and performance metrics and projections of market opportunity and expectations and the Company's acquisition pipeline. These statements are based on various assumptions and on the current expectations of AdaptHealth management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on, by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of the Company. These forward-looking statements are subject to a number of risks and uncertainties, including the outcome of judicial and administrative proceedings to which the Company may become a party or governmental investigations to which the Company may become subject that could interrupt or limit the Company's operations, result in adverse judgments, settlements or fines and create negative publicity; changes in the Company's customers' preferences, prospects and the competitive conditions prevailing in the healthcare sector. A further description of such risks and uncertainties can be found in the Company's filings with the Securities and Exchange Commission. If the risks materialize or assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that the Company presently knows or that the Company currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect the Company's expectations, plans or forecasts of future events and views as of the date of this press release. The Company anticipates that subsequent events and developments will cause the Company's assessments to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's assessments as of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements. Use of Non-GAAP Financial Information and Financial Guidance The Company uses Adjusted EBITDA and free cash flow, which are financial measures that are not in accordance with generally accepted accounting principles in the United States, or U.S. GAAP, to analyze its financial results and believes that they are useful to investors, as a supplement to U.S. GAAP measures. In addition, the Company's ability to incur additional indebtedness and make investments under its existing credit agreement is governed, in part, by its ability to satisfy tests based on a variation of Adjusted EBITDA. The Company believes Adjusted EBITDA is useful to investors in evaluating the Company's financial performance. The Company uses Adjusted EBITDA as the profitability measure in its incentive compensation plans that have a profitability component and to evaluate acquisition opportunities, where it is most often used for purposes of contingent consideration arrangements. Adjusted EBITDA should not be considered as a measure of financial performance under U.S. GAAP, and the items excluded from Adjusted EBITDA are significant components in understanding and assessing financial performance. Accordingly, these key business metrics have limitations as an analytical tool. They should not be considered as an alternative to net income or any other performance measures derived in accordance with U.S. GAAP or as an alternative to cash flows from operating activities as a measure of the Company's liquidity. The Company uses free cash flow, which is a financial measure that is not in accordance with U.S. GAAP, in its operational and financial decision-making and believes free cash flow is useful to investors because similar measures are frequently used by securities analysts, investors, ratings agencies and other interested parties to evaluate the Company's competitors and to measure the ability of companies to service their debt. The Company's presentation of free cash flow should not be construed as a measure of liquidity or discretionary cash available to the Company to fund its cash needs, including investing in the growth of its business and meeting its obligations. Free cash flow should not be considered as a measure of financial performance under U.S. GAAP. Accordingly, this key business metric has limitations as an analytical tool. It should not be considered as an alternative to any performance measures derived in accordance with U.S. GAAP or as an alternative to cash flows from operating activities as a measure of AdaptHealth's liquidity. This release contains non-GAAP financial guidance. There is no reliable or reasonably estimable comparable GAAP measure for the Company's non-GAAP financial guidance because the Company is not able to reliably predict the impact of certain items that typically have one or more of the following characteristics, such as being highly variable, difficult to project, unusual in nature, significant to the results of a particular period or not indicative of future operating results. Similar charges or gains were recognized in prior periods and will likely reoccur in future periods. As a result, reconciliation of the non-GAAP financial guidance to the most directly comparable GAAP measure is not available without unreasonable effort. In addition, the Company believes such a reconciliation would imply a degree of precision and certainty that could be confusing to investors. The variability of the specified items may have a significant and unpredictable impact on the Company's future GAAP results. In addition, the Company's financial guidance in this release excludes the impact of any potential additional future strategic acquisitions and any items that have not yet been identified and quantified. The financial guidance is subject to risks and uncertainties applicable to all forward-looking statements as described elsewhere in this press release.
Yahoo
08-05-2025
- Business
- Yahoo
AdaptHealth Corp (AHCO) Q1 2025 Earnings Call Highlights: Navigating Challenges with Strategic ...
The company reduced its full-year revenue expectations by $40 million and adjusted EBITDA expectations by $5 million due to the disposition of certain incontinence assets. Free cash flow was negative, and certain cash collections anticipated in the first quarter were pushed into the second quarter. Net revenue for the first quarter declined 1.8% compared to the prior year quarter, partly due to one less business day. AdaptHealth Corp ( NASDAQ:AHCO ) has a broad geographic footprint with over 660 locations, positioning it well to capture market share and lead the transformation of the home health industry. The company is on track to achieve its free cash flow guidance for the full year, with a significant improvement from negative $38.9 million in the prior year quarter to negative $0.1 million. AdaptHealth Corp ( NASDAQ:AHCO ) reduced its debt balance by $25 million in Q1, contributing to a total debt repayment of $195 million over the last five quarters. The Diabetes Health segment showed signs of recovery with sequential improvement in new starts and the best resupply attrition rate in two years. First quarter revenue exceeded the midpoint of guidance by $13.1 million, driven by strong performance in the Respiratory Health and Diabetes Health segments. Story Continues Q & A Highlights Q: Can you provide additional color on the improvements in the Diabetes business, particularly regarding growth in pumps and CGM? Also, is the guidance change only due to the incontinence asset sale? A: The guidance change is exclusively for the disposal of certain incontinence assets. Regarding diabetes, we saw positive movement in our pump business, showing growth over the first quarter of 2024. In CGMs, we experienced a second consecutive quarter of sequential growth in new starts, indicating a turnaround in the diabetes segment. - Jason Clemens, CFO Q: Regarding new starts in Sleep Health, is this a market issue or a market share issue? Are you losing share, and how do you plan to address it? A: Starts were slightly off, but it's not due to external factors. In certain geographies, we need to improve our setup speed and operations. We have detailed plans with our Commercial and operations teams to address these gaps, and we remain confident in our full-year guidance. - Jason Clemens, CFO Q: Can you clarify the impact of tariffs on your fiscal 2026 outlook, given recent developments? A: We are feeling better about our tariff exposure than we did previously. Many manufacturers received clarifications on their Nairobi classification, which may reduce our potential impact. We are not in a position to change our $10 million potential impact estimate for fiscal '26 yet, but the outlook is more positive. - Jason Clemens, CFO Q: There was a step-up in CapEx this quarter. Is this related to tariffs or increased demand? A: The increase in CapEx is due to outperformance in Respiratory Health, driven by increased sales during a heavy flu season. This is unrelated to tariffs and is a result of patient census growth in respiratory conditions. - Jason Clemens, CFO Q: Can you discuss the progress and future expectations for the One Adapt strategy? A: One Adapt focuses on leveraging our scale from past acquisitions to deliver operational efficiency and brand unity. We aim to simplify our entity structure and enhance our commercial team's reach to maximize patient access. This strategy is expected to drive growth in the back half of 2025 and into 2026. - Suzanne Foster, CEO For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Yahoo
06-05-2025
- Business
- Yahoo
AdaptHealth (NASDAQ:AHCO) Posts Better-Than-Expected Sales In Q1, Stock Jumps 13.2%
Healthcare services provider AdaptHealth Corp. (NASDAQ:AHCO) beat Wall Street's revenue expectations in Q1 CY2025, but sales fell by 1.8% year on year to $777.9 million. On the other hand, the company's full-year revenue guidance of $3.25 billion at the midpoint came in 0.5% below analysts' estimates. Its GAAP loss of $0.05 per share was significantly below analysts' consensus estimates. Is now the time to buy AdaptHealth? Find out in our full research report. AdaptHealth (AHCO) Q1 CY2025 Highlights: Revenue: $777.9 million vs analyst estimates of $764.8 million (1.8% year-on-year decline, 1.7% beat) EPS (GAAP): -$0.05 vs analyst estimates of $0.03 (significant miss) Adjusted EBITDA: $127.9 million vs analyst estimates of $127.3 million (16.4% margin, in line) The company dropped its revenue guidance for the full year to $3.25 billion at the midpoint from $3.29 billion, a 1.2% decrease EBITDA guidance for the full year is $685 million at the midpoint, in line with analyst expectations Operating Margin: 3%, down from 6.4% in the same quarter last year Free Cash Flow was -$58,000 compared to -$38.86 million in the same quarter last year Market Capitalization: $1.17 billion 'Amid elevated uncertainty in the external environment, we at AdaptHealth have stayed the course, with a relentless focus on improving our business and providing exceptional service to the 4.2 million patients that depend on us,' said Suzanne Foster, Chief Executive Officer of AdaptHealth. Company Overview With a network of approximately 680 locations serving patients across all 50 states, AdaptHealth (NASDAQ:AHCO) provides home medical equipment, supplies, and related services to patients with chronic conditions like sleep apnea, diabetes, and respiratory disorders. Sales Growth Examining a company's long-term performance can provide clues about its quality. Any business can have short-term success, but a top-tier one grows for years. Thankfully, AdaptHealth's 40.1% annualized revenue growth over the last five years was incredible. Its growth beat the average healthcare company and shows its offerings resonate with customers. AdaptHealth Quarterly Revenue We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. AdaptHealth's recent performance shows its demand has slowed significantly as its annualized revenue growth of 3.9% over the last two years was well below its five-year trend. AdaptHealth Year-On-Year Revenue Growth This quarter, AdaptHealth's revenue fell by 1.8% year on year to $777.9 million but beat Wall Street's estimates by 1.7%.
